Answers are grounded in this paper and cite their sources.
Clinical and preclinical studies have confirmed insulin-like growth factor-1 receptor (IGF-1R) antagonism can reduce the inflammation and proptosis occurring in thyroid eye disease (TED). We assessed the preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug (formerly VRDN-001), an anti-IGF-1R antibody in clinical development for TED. Veligrotug exhibited high-affinity binding to human IGF-1R protein (KD 0.55 nM) and IGF-1R endogenously expressed in HOCF cells (mean EC50 2.41 nM). Veligrotug did not bind to the insulin receptor in ELISA assays or inhibit insulin-mediated receptor phosphorylation in HepG2 cells. Binding epitope and antagonist properties were compared to teprotumumab (Tepezza®), a marketed anti-IGF-1R antibody. Mutational scan analysis demonstrated veligrotug and teprotumumab have overlapping but distinct binding epitopes. Veligrotug behaved as a full antagonist, providing near-complete inhibition of IGF-1 binding at ≥ 50 nM, in contrast to teprotumumab which plateaued at ~50% inhibition. Veligrotug provided near-complete inhibition of IGF-1R autophosphorylation and AKT phosphorylation, in contrast to partial inhibition by teprotumumab. Veligrotug pharmacokinetic parameters in cynomolgus monkeys were consistent with other human/humanized antibodies in monkeys: half-life was ~5–6 days, serum clearance was low (7.6‒12.9 mL/day/kg), and volume of distribution was low (64‒93 mL/kg). A robust pharmacodynamic response was observed after a single dose of veligrotug, with ~2.5-fold increases in IGF-1 levels that remained elevated throughout the dosing period for the 10 mg/kg and 50 mg/kg dose groups. Veligrotug’s pharmacologic, pharmacokinetic, and pharmacodynamic characteristics make it a good candidate for clinical development. Indeed, efficacy data at week 15 from two Phase 3 pivotal studies of veligrotug, THRIVE and THRIVE-2, showed statistically significant improvements in TED symptoms based on primary and secondary outcomes.
No takes yet. Share an insight, caveat, or question.
Kaplan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: